New approaches to the treatment of osteoporosis.
Although safe and effective agents are currently available to treat osteoporosis, fragility fractures remain a significant problem worldwide. Recent improvements in the understanding of the cellular, biochemical, and molecular pathways of bone biology have led to the development of newer agents to treat osteoporosis, which may lead to further improvements in outcomes. In this review, we summarize the most recent advances in the field, including new modes of administration of existing drug classes, various approaches to combination therapy, and drugs with novel mechanisms of action to treat osteoporosis.
Department of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil; Department of Medicine, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Barbara C
BC
Silva
John P
JP
Bilezikian
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors; D056657:Cathepsin K / Q000037:antagonists & inhibitors; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000378:metabolism; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D005819:Genetic Markers; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D053245:RANK Ligand / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism; D000077211:Zoledronic Acid
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D004164:Diphosphonates; D005819:Genetic Markers; D007093:Imidazoles; D010281:Parathyroid Hormone; D053245:RANK Ligand; C422903:SOST protein, human; D020845:Selective Estrogen Receptor Modulators; D012701:Serotonin; D000069448:Denosumab; D000077211:Zoledronic Acid; D056657:Cathepsin K